A new series of global health debates – Global Health Cafes – will kick off on Monday November 20th at the Royal Tropical Institute (KIT). The series is a joint collaboration between Vice Versa, Wemos and other civil society organizations, and will be facilitated by Petra Stienen, who will be joined by national and international experts on human resources for health.
In a letter to the director of the European Medicines Agency (EMA), three Members of European Parliament (MEPs) have expressed their concerns about vulnerable clinical trial participants in low- and middle-income countries. They urge the agency to be more transparent about its activities on protecting clinical trial participants and ethical testing of medicines in low- and middle-income countries. The letter refers to Wemos’ research report on unethical practices in clinical trials in African countries that was published earlier this year.
The European Parliament has rejected the European Commission’s proposed criteria for identifying endocrine-disrupting chemicals. These criteria, in their current form, would not sufficiently protect our health. The European Commission will therefore have to go back to the drawing board. Wemos applauds the Parliament’s decision, as this is another step closer towards protecting our health and environment.